Many investors seek to benefit from the rapid artificial intelligence industry (AI). One way to do this is to buy the shares of leading companies in this field, such as Nafidia. However, the chips maker was in a rupture in the best part of three years, and some may argue that it is currently exaggerated.
Another way to profit from artificial intelligence is to invest in players who focus on the least well -known AI. However, this strategy can only work if there are good reasons for the belief that the company concerned can recover.
With this background, let’s take a look at Amnesty International, which is still moving in the wrong direction: Pharmaceutical(Nasdaq: rxrx). Biotechnology (or techbio) has witnessed the share prices of 24 % already this year. Is it the time to buy stocks? Let’s look at one argument in favor of two arguments against investing in repeated drugs.
Photo source: Getty Images.
Amnesty International It can help reduce expenses and costs in many areas; Why not developing drugs? This is what Recursion Pharmaceuticals is betting on. The company uses an Atlantic algorithm to accelerate the initial stages of the process.
The development of new drugs is expensive, timetable and long. Most of the clinical compounds that reach human clinical trials eventually fail to reach the market. Despite the great technological progress during the past few decades, drug development work has become more challenging.
By predicting the lobster vehicles that are likely to be safe and effective through an artificial intelligence operating system that tests vehicles against a library of human genes, she hopes to increase the possibility of success, reduce the time of developing medicines, and increase sales (because it will make them in the market soon, they will generate revenues for longer periods before dealing with them before dealing with them before dealing with them. Patent slopes), And increasing profits.
If the company’s vision becomes a reality, it will turn the entire pharmaceutical industry, and repeated drugs may become incredibly successful in this process. This is an important reason to consider buying stocks.
Although the major vision of the Recursion Pharmaceuticals looks exciting, the market needs more than just a vision to reward stocks. It needs results. So far, the biotechnology company has little to be proud of it.
Although the lukear promises to transfer the way in which medicines are developed, the company does not have one drug on the market yet. Worse, he has no even candidate in clinical trials in the late stage.
Of course, this does not mean that the repetition approach does not work. Perhaps the company will be successful in the future. But in the meantime, the company’s lack of concrete evidence that not all words are just a major reason behind the move of its shares in the wrong direction.
Recursion Pharmaceuticals is not the only company that works in this project. It has at least a few competitors, some of whom recently got major victories.
For example, Eli Lily She recently entered into a partnership with high -minded high -sector drugs, which also use artificial intelligence in her approach to making medicines. ELI Lilly and Superlumalal will cooperate in using artificial intelligence to develop weight management treatments in a deal that could be worth 1.3 billion dollars for SuperLuminal.
Similar partnerships have signed partnerships, including with RushAnother pharmacist leader. Moreover, Recursion also built the largest volume in the pharmaceutical industry in cooperation with NVIDIA.
These factors may give a repetition in the race to master how artificial intelligence is used to develop treatments, but the profitable partnerships attracted by Lilly (and others) attracted that the race was not finished, and not through a long shot. It is difficult to predict who will appear victorious.
Drugs is the stock of biotechnology fraught with risk. It includes great upward potential if you can implement approximately impurities and prove that its approach is effective, but it can continue to move in the opposite direction and destroy the value of shareholders over the next five years. That is why investors who feel comfortable with risks and great fluctuations should look at the arrow; Until then, make sure it is a small part of your wallet.
Before purchasing stocks in the loads of medicines, consider this:
the Motley Adviser is a lie The analyst’s team has just identified what they think 10 best stocks For investors to buy now … RECURSION Pharmaceuticals has not been one of them. The ten shares that made the pieces can produce monster revenues in the coming years.
Look at when Netflix This list was submitted on December 17, 2004 … if you invest $ 1,000 at the time of our recommendation, You will have 649,657 dollars!* Or when Nafidia This list was presented on April 15, 2005 … if you invest $ 1,000 at the time of our recommendation, You will have 1,090,993 dollars!
Now, it is worth noting Stock consultant The total average return is 1057%-The superiority of the crushing in the market compared to 185 % on the S&P 500. Don’t miss the latest 10 best list, available when joining Stock consultant.
*The stock consultant dates back from August 18, 2025
Prosper Junior Btyy He has positions in Eli Lilly, Nvidia and Recursion Parmaceuticals. Motley is a lie that has positions in and recommends NVIDIA. Motley Fool Roche Holding Ag recommends. Motley deception has Disclosure.
